|
|
{{if listFind(vars.channel_names, "MSIF News")}} {{endif}}  {{if listFind(vars.channel_names, "MSIF News")}} {{endif}} {{if listFind(vars.channel_names, "MSIF News")}} 
MSIF News
{{endif}}
|
{{if listFind(vars.channel_names, "People With MS News")}} {{endif}}  {{if listFind(vars.channel_names, "People With MS News")}} {{endif}} {{if listFind(vars.channel_names, "People With MS News")}} 
Profile of the Month
{{endif}}
|
{{if listFind(vars.channel_names, "Research News")}} {{endif}}  {{if listFind(vars.channel_names, "Research News")}} {{endif}} {{if listFind(vars.channel_names, "Research News")}} 
Research News
{{endif}}
|
{{if listFind(vars.channel_names, "MS Society News")}} {{endif}}  {{if listFind(vars.channel_names, "MS Society News")}} {{endif}} {{if listFind(vars.channel_names, "MS Society News")}} 
MS News
{{endif}}
|
|
|
|
Making Connections
|
{{if listFind(vars.channel_names, "MSIF News")}}
|
|
MSIF News
 |
 |
| Summaries of new MSIF activities, events, projects, programmes, resources, publications and more. |
|
|
|
|
{{endif}}
{{if listFind(vars.channel_names, "People With MS News")}}
|
|
Profile of the Month
|
|
| Summaries of news, views and achievements from people with MS around the world. |
Profile of the Month : January 2010
Ahmed Darwish
Country: Egypt
Age: 47
Type of MS: Secondary progressive MS
Year of Diagnosis: 1992
There is a quote by Gandhi that inspires me, "Live as if you were to die tomorrow. Learn as if you were to live forever." I always have that quote in my mind and try to live by it.
 Deutsch English Español Français Italiano Русский
read more
|
|
|
|
{{endif}}
{{if listFind(vars.channel_names, "Research News")}}
|
|
Research News
|
|
| Summaries of all the latest research findings on MS selected by a team based at the Institute of Neurology, London. |
Efficacy of treatment of MS with IFN{beta}-1b or glatiramer acetate by monthly brain MRI in the BECOME study
In this randomised trial the efficacy of IFNb-1b (Betaferon/Betaseron®) and glatiramer acetate (GA, Copaxone®) were compared. Seventy-five people with RRMS were included in the study. After a 2-year treatment period the authors found no differences between the 2 groups in terms of MRI activity (new lesions and enhancing lesions) and clinical activity (new relapses).
authors: Cadavid D, Wolansky LJ, Skurnick J, Lincoln J, Cheriyan J, Szczepanowski K, Kamin SS, Pachner AR, Halper J, Cook SD
source: Neurology. 2009 Mar 11
read more
High field MRI in the diagnosis of multiple sclerosis: high field-high yield?
In this review the authors highlight the advantages of new high field MRI techniques in showing damaged regions in the brain that with conventional techniques (standard field strengths) cannot be visualised. This improvement in depicting changes in brain tissue may help us to better understand the underlying processes occurring in MS, which at the same time may have a number of practical applications.
authors: Wattjes MP, Barkhof F
source: Neuroradiology. 2009 Mar 11
read more
Pediatric optic neuritis: brain MRI abnormalities and risk of multiple sclerosis
The authors of this article aimed to investigate MRI factors involved in a higher risk of development of MS after an episode of optic neuritis in children. The risk of MS significantly increased in children with at least one lesion seen on a brain MRI performed during the episode of optic neuritis. Children with normal scans had a very low risk of developing MS.
authors: Bonhomme GR, Waldman AT, Balcer LJ, Daniels AB, Tennekoon GI, Forman S, Galetta SL, Liu GT
source: Neurology. 2009 Mar 10;72(10):881-5
read more
Measuring demyelination and remyelination in acute multiple sclerosis lesion voxels
It is known that the damage which occurs in the axons (specific parts of the neurons in charge of the conduction of electrical signal) is, at least partly, responsible for the development of disability in MS. It is also known that acute inflammation is involved in causing axonal damage. The authors of this study have validated the usefulness of a specific MRI technique (MTR) in monitoring the processes of damage (demyelination) and recovery (remyelination) which take place when an acute MS lesion appears, considering that the better the recovery the lower the probability of axonal damage.
authors: Giacomini PS, Levesque IR, Ribeiro L, Narayanan S, Francis SJ, Pike GB, Arnold DL
source: Arch Neurol. 2009 Mar;66(3):375-81
read more
Grey matter magnetization transfer ratio independently correlates with neurological deficit in secondary progressive multiple sclerosis
In this study the authors aimed to investigate, in people with secondary progressive MS, the correlation of disability with damage seen in the normal appearing brain tissue by means of a new MRI technique (MTR) and the lesion burden measured by means of conventional (T2-wighted) MRI. They found that the damage in the grey matter showed the strongest correlation with clinical outcome. These results highlight the usefulness of the MTR as a technique which accurately reflects brain tissue changes in MS (even better than conventional MRI) and also emphasise the role of the grey matter in the development of disability.
authors: Hayton T, Furby J, Smith KJ, Altmann DR, Brenner R, Chataway J, Hughes RA, Hunter K, Tozer DJ, Miller DH, Kapoor R
source: J Neurol. 2009 Mar 6
read more
Neutralizing antibodies in multiple sclerosis patients treated with 375 mug interferon-beta-1b
The IFN-beta represents one of the most widely used treatments in MS. Nevertheless, its efficacy might be diminished by the presence of neutralising antibodies (NAbs), which reflect an immune reaction against the treatment. In this multicentre study the authors looked at the harmful effects produced by NAbs on clinical and MRI outcomes produced by NAbs. They found that even though MRI parameters showed worse evolution in people with higher NAbs frequency, no effect of NAbs on clinical outcome was observed.
authors: Durelli L, Barbero P, Cucci A, Ferrero B, Ricci A, Contessa G, De Mercanti S, Ripellino P, Lapuma D, Viglietta E, Bergui M, Versino E, Clerico M
source: Expert Opin Biol Ther. 2009 Mar 11
read more
|
|
|
|
{{endif}}
{{if listFind(vars.channel_names, "MS Society News")}}
|
|
MS News
|
|
| Summaries of MS news from websites around the world. |
|
{{endif}}
|
|
Tell a friend
The email you subscribed with us is {{print email}}
Within this newsletter the following options are available: MSIF News; People with MS News; Research News and MS Society News. To amend your options please login to the 'My world of MS' online community where you can also read diary entries from people affected by MS, leave your own diary entries and send messages to other users. You can also change your email address, contact details and subscribe to our free publications.
If you have an RSS News Reader you can get the latest news syndicated to you by copying the following link to your Reader: Syndicate.
If you do not want to receive future issues of this newsletter or if you have received this in error, please accept our apologies and simply unsubscribe here
Multiple Sclerosis International Federation
3rd Floor Skyline House, 200 Union Street, SE1 0LX
Tel: +44 (0) 20 7620 1911
Fax: +44 (0) 20 7620 1922
Registered Charity: 1105321
Email: info@msif.org
|
|
